Approval Granted for Huadong Medicine's Liraglutide Injection as the First Domestic GLP-1 Weight-Loss Drug

According to the latest search results, the market approval application for Liraglutide Injection by Huadong Medicine for the indication of obesity or overweight has been granted. This is the first approved GLP-1 class weight-loss drug in China and holds significant importance for the treatment of the obese population.

Here is some important information about Liraglutide Injection:

Introduction to Liraglutide Injection

Liraglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist with 97% sequence homology to human GLP-1.
Liraglutide has already been approved for improving glycemic control in adults with type 2 diabetes mellitus (T2DM) and for the treatment of obesity or overweight patients.
Expansion of Indications for Liraglutide Injection

The market approval application for the indication of obesity or overweight for Liraglutide Injection has been granted.
This makes Huadong Medicine the first pharmaceutical company in mainland China to receive market approval for Liraglutide Injection in the indication of obesity or overweight.
Significance of the Obesity Issue

The proportion of the global population affected by obesity continues to rise, highlighting the increasing importance of addressing overweight issues.
According to the "2019 Report on Chinese Residents' Nutrition and Chronic Disease Status," over 50% of adult residents in China are overweight or obese, and the rate of overweight/obesity in children is also high.
Obesity and overweight increase the risk of various systemic diseases and significantly impact quality of life.
Importance of GLP-1 Receptor Target

GLP-1 receptor has become a mainstream target for the development of weight-loss drugs.
GLP-1 class products have demonstrated efficacy in weight reduction, blood glucose control, and cardiovascular benefits. They are considered relatively mature, stable, and safe targets.
Market Outlook and Impact

The availability of Liraglutide Injection will provide more treatment options for obese and overweight patients.
This represents an important market opportunity for Huadong Medicine, as it will complement the company's existing product line in the endocrine field, synergizing with their existing Orlistat capsules for both clinical and inpatient/outpatient markets.

In conclusion, the market approval application for Huadong Medicine's Liraglutide Injection for the indication of obesity or overweight has been granted. It is expected to become the first domestically produced GLP-1 class weight-loss drug, holding significant importance for the treatment of the obese population.